Bowen disease is the early form of squamous cell carcinoma and is also known as squamous cell carcinoma in situ. For instance, according to an article published by the Open Access Macedonian Journal of Medical Sciences in February 2019, it is estimated that around 3- 5% of noninvasive Bowen disease develops into an invasive squamous cell carcinoma, a more serious form of skin cancer which can spread throughout the body. Bowen disease is characterized by the presence of red scaly patches or lesions on various parts of the body which are most exposed to the sun such as hands, legs, feet, and others. These lesions or scaly patches are usually asymptomatic i.e. they are usually not associated with symptoms such as pain, bleeding, and others. Some of the risk factors associated with Bowen disease include ionizing radiation, human papillomavirus (HPV) infection, sun exposure, exposure to arsenic, immunosuppressive drugs, and others. In cases, where Bowen disease affects the genitals in men, it is known as erythroplasia of Queyrat. Bowen disease can be diagnosed with the help of a tissue biopsy of the affected area and can be treated using chemotherapy, cryotherapy, photodynamic therapy, surgery, and others.
The global Bowen disease treatment market is estimated to be valued at US$ 356.5 million in 2021 and is expected to exhibit a CAGR of 4.5% over the forecast period (2021-2028).
Figure 1. Global Bowen Disease Treatment Market Share (%), By Region, 2021
The increasing incidence of squamous cell carcinoma in situ (Bowen disease) is expected to drive the growth of the global Bowen disease treatment market over the forecast period.
For instance, according to an article published by the JAMA Dermatology journal in July 2020, a study of 88,754 patients suffering from Bowen disease in Netherlands between January 1, 1989, and December 31, 2017 reveals that the incidence of Bowen disease (cutaneous squamous cell carcinoma in situ) had increased from 1989 to 2017 in Netherlands with the highest incidence of Bowen disease in 2017. The incidence rate was found to be 71.7 cases per 100,000 person-years in 2017 among women and 540.9 cases per 100,000 person-years among men.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 356.5 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 4.5% | 2028 Value Projection: | US$ 546.8 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Galderma S.A., Sirnaomics, Inc., PEPLIN INC, Ponce Therapeutics, Intas Laboratories Pvt Ltd, Cadila, Pharmaceuticals Ltd., VHB Life Sciences Limited, Neon Laboratories Ltd, Teva Pharmaceutical Ltd, and Actavis Group |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2. Global Bowen Disease Treatment Market Value (US$ Mn), By Drug Type, 2021
The increasing research and development activities for the development of novel therapeutics for the treatment of Bowen disease is expected to drive the market growth over the forecast period.
For instance, in February 2021, Ponce Therapeutics, a U.S. based biotechnology company, announced the launch of its first research and development plan for the treatment of skin conditions such as Bowen disease, aging, and others. The company has hired its first scientists for executing its research and development plan. The research and development plan would majorly focus on p16 cell proliferation inhibitor, which is highly expressed in Bowen disease. This research and development plan would thus help in development of the company’s first product for regulatory approval as well as launch.
Global Bowen Disease Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 252,826,597 cases and 5,092,761 deaths due to coronavirus (COVID-19) were reported till November 14, 2021, across the globe.
The COVID-19 pandemic and lockdown in various countries across the globe has negatively impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. Likewise, COVID-19 pandemic is expected to have a negative impact on the global Bowen disease treatment market over the forecast period, owing to disruption in cancer treatment services and halt of clinical trials related to treatment of cancer (including Bowen disease). For instance, according to a report published by the World Health Organization in July 2020, around 42% of the countries across the world have disrupted services for cancer treatment in lieu of COVID-19 pandemic.
Global Bowen Disease Treatment Market Restraint
The side effects of chemotherapy drugs used in the treatment of Bowen disease are the factors that are expected to hinder growth of the global Bowen disease treatment market over the forecast period. For instance, according to an article published by the StatPearls journal in July 2021, topical application of fluorouracil, a chemotherapy drug used for treatment of Bowen disease is associated with adverse effects such as pain, crusting, erythema, and others.
Key Players
Major players operating in the global Bowen disease treatment market include Galderma S.A., Sirnaomics, Inc., PEPLIN INC, Ponce Therapeutics, Intas Laboratories Pvt Ltd, Cadila, Pharmaceuticals Ltd., VHB Life Sciences Limited, Neon Laboratories Ltd, Teva Pharmaceutical Ltd, and Actavis Group
Bowen disease, also called as squamous cell carcinoma in situ, is a rare type of skin disorder characterized by development of slow-growing, red/pink scaly patches on the skin. These scaly patches are mostly observed in those areas of the body which are exposed to sun such as hands, legs, and others. Bowen disease is a noninvasive form of intraepidermal squamous cell carcinoma, which occurs only inside the epidermal (outer) layer of the skin. Scaly patches or lesions associated with Bowen disease are usually not painful and are easily treatable. These lesions may be flat or slightly raised and are usually not associated with any symptoms, but sometimes these lesions can show symptoms such as itch, pus, bleeding, and others. Lesions tend to grow very slowly over months or years, and can develop into squamous cell skin cancer if untreated. There is no proven cause of Bowen disease yet, but risk factors such as sun exposure, human papillomavirus (HPV) infection, immunosuppressive drugs, and others increase the risk of Bowen disease incidence.
Market Dynamics
The increasing incidence of Bowen disease, rising research and development activities for the development of novel therapeutics for the treatment of Bowen disease are the major factors that are expected to drive growth of the global Bowen disease treatment market over the forecast period. Moreover, increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are expected to boost the global Bowen disease market.
For instance, according to an article published in the Dermatologic Surgery journal in November 2019, the annual age-standardized incidence rates of Bowen disease in Caucasian population in Northern Europe per 100,000 people was found to be increased from 8.1 in 2003 to 68.9 in 2013 and is expected to increase in near future.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients